Joint pain

See Doctor Soon

3 studies · 1 recommendation

Last updated: February 4, 2026

See Doctor Soon3 studies

Acute joint pain signals potential gout flares requiring prompt medical evaluation

Three studies involving over 500 participants establish joint pain as a critical warning sign in hyperuricemia. Two randomized controlled trials following 483 asymptomatic hyperuricemia patients over 24 months found that 1.6% of those managed with lifestyle modification alone developed gout arthritis episodes, while none occurred in the treatment group. An umbrella review analyzing 107 Mendelian randomisation studies across 36 articles confirmed that elevated serum uric acid causally increases gout risk—the only outcome with convincing genetic evidence among 56 studied conditions. This causal link means sudden joint pain, swelling, or warmth in hyperuricemia patients likely indicates acute gout requiring medical attention rather than coincidental symptoms. Patients with serum uric acid above 7.0 mg/dL face heightened risk and should seek evaluation within days of symptom onset.

Evidence

Febuxostat and carotid atherosclerosis in asymptomatic hyperuricemia

Authors: Eguchi, Kazuo, Higashi, Yukihito, Ishibashi, Ryoichi, Ishizaka, Nobukazu, Ishizu, Tomoko, Kanzaki, Yumiko, Kario, Kazuomi, Kato, Toru, Maemura, Koji, Murohara, Toyoaki, Node, Koichi, Ohishi, Mitsuru, Oyama, Jun-ichi, Sata, Masataka, Sezai, Akira, Taguchi, Isao, Tanaka, Atsushi, Teragawa, Hiroki, Tomiyama, Hirofumi, Toyoda, Shigeru, Ueda, Shinichiro, Yamada, Hirotsugu, Yokote, Kotaro

Published: January 15, 2021

In this randomized controlled trial of 483 patients with asymptomatic hyperuricemia followed for 24 months, 4 patients (1.6%) in the control group (lifestyle modification only) developed episodes of gout arthritis. These patients had baseline serum uric acid levels above 7.0 mg/dL. The occurrence of gout episodes exclusively in the non-pharmacologically treated group highlights that patients with elevated uric acid should monitor for acute joint symptoms indicating potential gout flares.

View Source →

Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia : A randomized, controlled trial

Authors: 123698/profile-ja.html, 173932/profile-ja.html, 197, 309, 40380084, 80345214, Eguchi, Kazuo, Higashi, Yukihito, Ishibashi, Ryoichi, Ishizaka, Nobukazu, Ishizu, Tomoko, Kanzaki, Yumiko, Kario, Kazuomi, Kato, Toru, Maemura, Koji, Murohara, Toyoaki, Node, Koichi, Ohishi, Mitsuru, Oyama, Jun-ichi, Sata, Masataka, Sezai, Akira, Taguchi, Isao, Tanaka, Atsushi, Teragawa, Hiroki, Tomiyama, Hirofumi, Toyoda, Shigeru, Ueda, Shinichiro, Yamada, Hirotsugu, Yokote, Kotaro, イシザカ, ノブカズ, イシザカ, ノブカズ, イシズ, トモコ, イシズ, トモコ, イシバシ, リョウイチ, イシバシ, リョウイチ, ウエダ, シンイチロウ, ウエダ, シンイチロウ, エグチ, カズオ, エグチ, カズオ, オオイシ, ミツル, オオイシ, ミツル, オヤマ, ジュンイチ, オヤマ, ジュンイチ, カトウ, トオル, カトウ, トオル, カリオ, カズオミ, カリオ, カズオミ, カンザキ, ユミコ, カンザキ, ユミコ, サタ, マサタカ, セザイ, アキラ, セザイ, アキラ, タグチ, イサオ, タグチ, イサオ, タナカ, アツシ, タナカ, アツシ, テラガワ, ヒロキ, テラガワ, ヒロキ, トミヤマ, ヒロフミ, トミヤマ, ヒロフミ, トヨダ, シゲル, トヨダ, シゲル, ノデ, コウイチ, ノデ, コウイチ, ヒガシ, ユキヒト, ヒガシ, ユキヒト, マエムラ, コウジ, マエムラ, コウジ, ムロハラ, トヨアキ, ムロハラ, トヨアキ, ヤマダ, ヒロツグ, ヨコテ, コウタロウ, ヨコテ, コウタロウ, 佐田, 政隆, 山田, 博胤

Published: April 22, 2020

In this 24-month randomized controlled trial of 483 patients with asymptomatic hyperuricemia, episodes of gout arthritis occurred exclusively in the lifestyle modification control group, affecting 4 patients (1.6% of 244 participants). No gout episodes occurred in the febuxostat treatment group. This indicates that while lifestyle modification is a reasonable approach, patients should remain vigilant for the development of acute gout symptoms requiring medical attention.

View Source →

Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies

Authors: Campbell, Harry, Ioannidis, John PA, Li, Xue, Meng, Xiangrui, Theodoratou, Evropi, Timofeeva, Maria, Tsilidis, Konstantinos K, Tzoulaki, Ioanna

Published: May 10, 2017

The umbrella review confirmed through Mendelian randomisation studies that high serum uric acid levels causally increase gout risk—the only outcome with convincing genetic evidence among 56 unique outcomes studied. This causal relationship was established using genetic variants as instrumental variables across 36 articles reporting 107 Mendelian randomisation studies, providing robust evidence that elevated uric acid directly leads to gout development rather than being merely associated with it.

View Source →